[Is primary or secondary prevention of diabetes mellitus in hyperliporoteinemia possible under long-term clofibrate therapy?].
The investigations of metabolism explained speak for an improved condition of the carbohydrate metabolism during the first months of the therapy. However, they are not sufficient to prove a preventive effect of clofibrat per se during long-term treatment. Our examinations by means of the glucose infusion test show that on certain defined conditions with intensive general treatment positive effects may be registered, which, however, cannot be reproduced in a large collective during outpatient care. On the contrary, it is to be assumed that the whole therapeutic regime has an influence. Nevertheless, one may establish that the incidence portion of the diabetes manifestation in patients with hyperlipoproteinaemia treated with regadrin corresponds nearly to that one of the average population of Dresden. It is puzzling that the death rate in patients with hyperlipoproteinaemia and diabetic condition of metabolism is significantly higher than in hyperlipoproteinaemia without disturbance of the carbohydrate metabolism.
D002994:Clofibrate / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy; D008134:Long-Term Care; D008875:Middle Aged; D013997:Time Factors
D002994:Clofibrate
Ist undter Langzeittherapie mit Clofibrat eine primäre oder sekundäre Prävention des Diabetes mellitus bei Hyperlipoproteinämie möglich